Cell-mediated immune responses to COPV early proteins

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

Jan M.M. Walboomers, Marcel V. Jacobs, M. Michele Manos et al. · The Journal of Pathology · 1999 · 9K citations

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

Diane M. Harper, Eduardo L. Franco, Cosette M. Wheeler et al. · The Lancet · 2004 · 1.6K citations

Vaccination, Vaccine Safety, Vaccine Development +6

A Controlled Trial of a Human Papillomavirus Type 16 Vaccine

Laura A. Koutsky, Kevin A. Ault, Cosette M. Wheeler et al. · New England Journal of Medicine · 2002 · 1.6K citations · Full text

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Luisa L. Villa, Ronaldo Lúcio Rangel Costa, Carlos Alberto Petta et al. · The Lancet Oncology · 2005 · 1.6K citations

Vaccination, Vaccinology, Vaccine Development +9

Carcinogenicity of human papillomaviruses

Vincent Cogliano, Robert A. Baan, Kurt Straíf et al. · The Lancet Oncology · 2005 · 692 citations

Cervical Cancer, Precancerous Lesions, Human Papillomavirus Vaccines +10